about
Improved plaque assay identifies a novel anti-Chlamydia ceramide derivative with altered intracellular localizationHeat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.Small molecule inhibitors of ceramidases.CFTR and sphingolipids mediate hypoxic pulmonary vasoconstrictionSmall molecule inhibitors of acid sphingomyelinase.The cellular ceramide transport protein CERT promotes Chlamydia psittaci infection and controls bacterial sphingolipid uptake.A series of ceramide analogs modified at the 1-position with potent activity against the intracellular growth of Chlamydia trachomatis.Perspectives in targeting miRNA function.MicroRNA maturation and human disease.Labeled chemical biology tools for investigating sphingolipid metabolism, trafficking and interaction with lipids and proteins.miRNAs as novel therapeutic targets and diagnostic biomarkers for Parkinson's disease: a patent evaluation of WO2014018650.Inhibitors of Ceramidases.Recent advances and novel treatments for sphingolipidoses.Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.Amplification of a FRET Probe by Lipid-Water Partition for the Detection of Acid Sphingomyelinase in Live Cells.Elemental labelling and mass spectrometry for the specific detection of sulfenic acid groups in model peptides: a proof of concept.Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase.Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology.Development of carbohydrate-derived inhibitors of acid sphingomyelinase.Potent inhibition of acid sphingomyelinase by phosphoinositide analogues.Long endogenous dsRNAs can induce complete gene silencing in mammalian cells and primary cultures.Structural insights into adiponectin receptors suggest ceramidase activity.Rolling-circle amplification: unshared advantages in miRNA detection.Synthesis and biochemical investigation of scyphostatin analogues as inhibitors of neutral sphingomyelinase.A chemo-enzymatic approach to specifically click-modified RNA.Facile synthesis of the CERT inhibitor HPA-12 and some novel derivatives.MicroRNA-145-targeted drug and its preventive effect on pulmonary arterial hypertension (patent WO2012153135 A1).Differential-Mobility Spectrometry of 1-Deoxysphingosine Isomers: New Insights into the Gas Phase Structures of Ionized Lipids.Detection of microRNA maturation using unmodified pre-microRNA and branched rolling circle amplification.Assaying Dicer-mediated miRNA maturation by means of fluorescent substrates.Lung endothelial Ca2+ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6.DNA made of purines only.A Scaffold-Tree-Merging Strategy for Prospective Bioactivity Annotation of γ-PyronesDevelopment of an assay for the intermembrane transfer of cholesterol by Niemann-Pick C2 proteinFRET probes for measuring sphingolipid metabolizing enzyme activityRegioselective Diazo-Transfer Reaction at the C3-Position of the 2-Desoxystreptamine Ring of Neamine AntibioticsStructure of a human intramembrane ceramidase explains enzymatic dysfunction found in leukodystrophyRNA interference: from an ancient mechanism to a state of the art therapeutic application?Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase This work was supported by grants from the Fonds der Chemischen Industrie. C.A. is grateful to the Land of Baden-Württemberg for a scholarship from the LandesgraduieManumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase
P50
Q34057486-E1DDA9B4-42A9-4343-85C9-C0F384A840C4Q34539778-1DDE4816-32BA-43A2-B751-AEB20264C3F6Q35197450-7991370F-1F4A-4F26-ADCC-8255B0852DF3Q35279508-C865408B-313C-49D9-BFB5-47B34628828FQ37760683-6488D6DA-4231-4784-A641-D99EBD52CAEEQ37834089-121DC22F-A86B-402F-902B-DE42BA9A4952Q37838706-4B63CCAC-1D2F-42F5-83AE-87E489E3E3B2Q38100468-CB073C61-A9E9-4F04-8D57-12B5B61C7BB3Q38156072-11BDDD0B-9911-456F-B361-B179BCDED459Q38175755-32B10C33-4829-46D7-8553-0D4167F297CBQ38259297-2852C830-ED25-44A5-899E-763225D57F4CQ38556579-E87AE67A-278C-4A31-B3EC-B975CA50E4B7Q38635135-B656E192-D391-44E8-A637-43000E89E14EQ38751590-219FD7C4-9FAA-42E1-AC7E-72C3F2125817Q38762263-0A4A9B64-6853-4D2C-A893-6492944F233CQ38769223-B05F5626-F5A5-48FB-80E9-036CBA94E71AQ39096709-54A0E96B-1865-4F85-8C58-D929C62CD607Q39746539-50FA2796-E5C7-4746-8FC7-1AC986861983Q39764225-00A8A9EF-DC6C-4501-A11A-FC532E95FABBQ39811319-DB157B9F-DC51-4173-9DF8-9F058E1D4D70Q40582399-F334E79E-883A-4327-8035-297B1598F345Q41232999-22C5D330-2150-437F-9C36-85BBAB809195Q43575934-5025A3DA-1F7F-4846-BFF4-51FA46F4E3EAQ43764178-3807A962-3891-45E6-8F4D-F6ABD23C31CAQ45902544-C61FF411-55CF-4976-8B82-49FB3FD2D9C9Q46395685-B17D3243-41CE-46A1-A40B-28F6535DD2D3Q48045287-31293CF1-DD11-4284-8F20-23722B3ABA76Q52613570-AD579C8C-5572-4E0F-9D48-62DF6A942822Q52882012-83C700EE-C162-4A04-A4F9-0A54DCD7ACC5Q52882015-527AE6E7-8EF2-4B80-A881-C8DB27527990Q52890205-A61CEE93-0BDD-4742-88BC-EFF35E388C5FQ52925875-94308372-00DC-4A23-A787-3F95BDA5BAA1Q57006878-C033F114-5F50-4690-A1C1-0511CE91425FQ57375648-51D040B9-1CF6-47E4-B028-EE6D34CE66C5Q57779643-61A0D20F-48DC-4724-8B5C-26E23FF44082Q58034197-9D8F0874-78A7-4E8D-98B6-F95B06E58FCAQ60300327-F5FEE352-28AF-496A-8B1F-D30E83B4334BQ61480518-CF6291BF-DEEA-446C-B459-1475B705C9C7Q73704220-66B3BA9C-E60D-43A7-A4AE-3E68E144E39FQ77596715-C249CEAE-7880-460B-9871-DD010F6D01B5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christoph Arenz
@ast
Christoph Arenz
@en
Christoph Arenz
@es
Christoph Arenz
@nl
type
label
Christoph Arenz
@ast
Christoph Arenz
@en
Christoph Arenz
@es
Christoph Arenz
@nl
prefLabel
Christoph Arenz
@ast
Christoph Arenz
@en
Christoph Arenz
@es
Christoph Arenz
@nl
P106
P1153
6603725566
P31
P496
0000-0001-7613-9437